This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Syneron Medical's CEO Discusses Q1 2012 Results - Earnings Call Transcript

Stocks in this article: ELOS

International sales grew 24% during the first quarter. These results were mainly driven by strong performance in ENMEA and Japan and successful continued rollout of our eTwo and eLace products.

North American sales rose 30% year over year. Of major significance in North America results is the launch of the GentleMax Pro during the quarter and market traction from our other recently-launched products.

Recurring revenue, which includes service and consumables, were up 4% representing approximately 31% of total PAD sales.

In the PAD segment, revenue increased 21% and non-GAAP operating income was $4.6 million, or 8.1% of PAD sales.

In EBU, revenue rose 111%. The EBU continued to generate an operating loss for the quarter. In addition, EBU sales were negatively impacted by the previously-announced voluntary field action we had [inaudible] the Lifetouch laser systems in Europe, which resulted in virtually no revenue for the product in the quarter.

We regained CE preformity to the Lifetouch system and remain on track to fully address the issue by the end of the third quarter of this year.

Excluding the Lifetouch business, EBU sales from Syneron Beauty Products and elure increased over 250% over the prior year, demonstrating the continued high-growth trajectory for this segment.

On a consolidated basis, we achieved non-GAAP operating income of over $700,000 and non-GAAP earnings of $0.02 per share. This is our sixth consecutive quarter of non-GAAP profitability.

During first quarter, we completed several important operational milestones that will contribute to both our near-term and long-term success.

In February, we acquired Ultrashape, paving the way for our entry into non-invasive fat cell destruction and body sculpting market. Since the closing, we’ve been working closely with our new colleagues from Ultrashape to integrate the business with Syneron.

Read the rest of this transcript for free on seekingalpha.com

3 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs